Latest AVI BioPharma Stories
Ebola may soon be easier to fight thanks to a new treatment being tested by US scientists.
New publication in Molecular Therapy outlines dramatic effects in animals treated with splice switching PPMO, demonstrates promise for treatment of Duchenne muscular dystrophy.
AVI BioPharma, a developer of RNA-based drugs, has announced that its partner Global Therapeutics, a Cook Medical company, has initiated a clinical trial of a drug eluting stent that uses a peptide-conjugated morpholino phosphorodiamidate oligomer-based RNA therapeutic agent aimed at silencing C-MYC, one of the genes responsible for causing arteries to reclose after stenting.
AVI BioPharma has announced that the European Medicines Agency Committee for Orphan Medicinal Products adopted a positive opinion recommending orphan medicinal product designation for AVI-4658 to treat Duchenne muscular dystrophy.
AVI BioPharma, Inc.
AVI BioPharma, Inc.
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Leslie Hudson, AVI's President and CEO, will present at two upcoming healthcare conferences.
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Leslie Hudson, AVI's President and CEO, will present an update on the continuing transition of AVI from an antisense pioneer into a leading discoverer and developer of RNA-based drugs.
AVI BioPharma, Inc. (NASDAQ: AVII) announced today that it will host a breakfast meeting for analysts, brokers, investors and the Company's shareholders on Wednesday, September 10, 2008, from 7:30 a.m. to 10:30 a.m. EDT at the Harvard Club of New York City.
AVI BioPharma, Inc. (NASDAQ: AVII) today reported financial results for the three and six months ending June 30, 2008.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.